Zoetis Services LLC

Abbott Laboratories Corporation

Janssen Pharmaceutica Nv

Zoetis LLC

Ah USA 42 LLC

Michael P Curtis

Richard Andrew Ewin

Graham M Kyne

Cheryl A Grice

Marlon D Cowart

Robert J Altenbach

Lawrence A Black

Gregory A Gfesser

Yi-Yin Ku

Huaqing Liu

Ramin Faghih

Kirill A Lukin

Sou-Jen Chang

Diana L Nersesian

Paul D Johnson

Rajendran Vairagoundar

Yu-Ming M Pu

Susan M K Sheehan

Matthew W Bedore

Yu-Ming Pu

James Patrick Edwards

Youssef L Bennani

Valerie Ann Vaillancourt

Brad M Savall

Laurent Gomez

Timothy Allan Johnson

Nathan Anthony Logan Chubb

Padam N Sharma

Frank Chavez

Aaron M Kearney

Tomasz Respondek

Sanjay Menon

John Adam Wendt

Tom L McTier

Susan M Sheehan

Christopher Scott Knauer

Michael Anthony Letavic

Neelakandha S Mani

Peter Laurence Toogood

John M Keith

Jing Liu

Govindan Subramanian

Edmund Lee Ellsworth

Emily M Stocking

Brett D Allison

Joseph Scott Warmus

Denis Billen

Anne E Fitzgerald

Todd M Maddux

Donald James Skalitzky

Timothy Lee Stuk

Manjinder Singh Lall

Susan Mary Kult Sheehan

Jinxia (Nancy) Deng

Jennifer M B Miller

William Howson

Sean David William Greenwood

Christoper S Knauer

Jinxia Deng

The present invention provides cyclic depsipeptides of Formula (1), stereoisomers thereof, and veterinary acceptable salts thereof wherein each of R, R, R, R, L, and L, are as defined herein. The present invention also contemplates compositions and methods of treatment as an endoparasiticide with a Formula (1) compound.

Endoparasitic depsipeptides

The present invention provides cyclic depsipeptides of Formula (1), stereoisomers thereof, and veterinary acceptable salts thereof wherein each of R, R, R, R, L, and Lare as defined herein. The present invention also contemplates compositions, methods of treatment, and uses as a medicament to treat an animal for an endoparasitic infection with a Formula (1) compound.

The present invention provides Formula (1) compounds that are gamma-carbolines, Formula (1) wherein R1, R1, R1, R1, R2, R3, and '-' are as defined herein; veterinary acceptable salts thereof, and stereoisomers thereof, which act as parasiticides, in particular, endoparasiticides.

Carboline antiparasitics

The present invention provides novel phenicol derivatives, their use for the treatment of infections in mammals, pharmaceutical composition containing these novel compounds, and methods for the preparation of these compounds.

Phenicol antibacterials

Described herein are antibacterial compounds of formula I, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical composition.

Tricyclic tetrahydroquinoline antibacterial agents

The invention recites spirocyclic isoxazoline derivatives of Formula (V.1), Formula (V.2), Formula (V.1.1), and Formula (1) stereoisomers thereof, veterinarily acceptable salts thereof, compositions thereof, processes for making, and their use as a parasiticide in an animal. The variables A, V, Z, W, W, W, W, Y, X, R, R, R, R, R, R, n, and '' are as described herein.

Spirocyclic isoxazoline derivatives as antiparasitic agents

This invention recites isoxazoline substituted azetidine derivatives of Formula (1) stereoisomers thereof, veterinarily acceptable salts thereof, compositions thereof, and their use as a parasiticide in mammals and birds. R, R, R, R, R, R, R, and n are as described herein.

Isoxazoline derivatives as antiparasitic agents

This invention recites naphthyl isoxazoline oxime derivatives of Formula (1) geometric isomers, stereoisomers thereof, pharmaceutically or veterinarily acceptable salts thereof, compositions thereof, and their use as a parasiticide in animals. The variables, R, R, R, R, R, andare as described herein.

Isoxazoline oximes as antiparasitic agents

Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

Bicyclic-substituted amines as histamine-3 receptor ligands

Benzofuro- and benzothienopyrimidine compounds are described, which are useful as Hreceptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by Hreceptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

[object Object]

Certain substituted benzyl amine compounds are histamine Hreceptor and/or serotonin transporter modulators useful in the treatment of histamine Hreceptor- and/or serotonin-mediated diseases.

Substituted benzyl amine compounds

Compounds of formula (I) wherein Ror Ris an aromatic or non-aromatic ring directly joined or joined by a linker, as represented by Land L, to a heteroaromatic core, and X, X', Y, Y&#x2032;, Z, Z&#x2032;, R, R, R, R, R, R, R, L, L, and Lare as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

Bicyclic-substituted amines having cyclic-substituted monocyclic substituents

Growing community of inventors

Portage, MI, United States of America

Michael P Curtis